John Byon MD

Senior VP Clinical Development

PhD

Dr. Byon has extensive oncology drug development experience in the pharmaceutical and biotechnology industry. At Genentech, he worked on TecentriqÆ (atezolizumab) in hematological malignancies. For over the past 5 years, he has worked in the cell therapy space. First at Juno as the Global Development Lead for orvacabtagene autoleucel (JCARH-125) in Multiple Myeloma. Then at Lyell, working on next generation cell therapy products for solid tumors. Most recently, he was VP, Clinical Development Hematology at Fate Therapeutics, where he oversaw a portfolio of 5 iPSC-derived cell therapies (CAR-NK and CAR-T) in a various hematologic malignancies (AML, MM, B-cell Lymphoma).

Back